The FZD2 level can be used to predict median overall survival (OS), the degree of immune cell infiltration, and the immune response of gastric cancer patients and to assess the effect of immunotherapy, with FZD7 expression suggesting a higher gastric cancer incidence and lymph node metastasis (42, 43). This evidence concerns the gene FZD2 and gastric cancer.